Institutional Ownership
Kiniksa Pharmaceuticals Intl
CUSIP G52694109ORD SHS CL AQ1 2026
13D / 13G Filings
13
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
11.0%
Max % of class reported
Institutional Holders
219
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
13 filings · latest Mar 6, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 6, 2026 | Fmr LLC | 13G | 10.6% | 4.85M | SEC |
| 2 | Feb 13, 2026 | Rubric Capital Management LP | 13G/A | 7.4% | 3.33M | SEC |
| 3 | Oct 31, 2025 | The Vanguard Group | 13G/A | 7.0% | 3.06M | SEC |
| 4 | Jul 17, 2025 | Blackrock, Inc. | 13G/A | 1.0% | 418.2K | SEC |
| 5 | Jul 9, 2025 | Rubric Capital Management LP | 13G/A | 9.2% | 3.91M | SEC |
| 6 | May 14, 2025 | Rubric Capital Management LP | 13G/A | 8.1% | 3.38M | SEC |
| 7 | Apr 23, 2025 | Blackrock, Inc. | 13G/A | 5.4% | 2.26M | SEC |
| 8 | Apr 4, 2025 | Tang Capital Management, LLC | 13G | 5.2% | 2.18M | SEC |
| 9 | Feb 14, 2025 | Fairmount Funds Management LLC | 13G/A | 11.0% | 9 | SEC |
| 10 | Nov 14, 2024 | Fairmount Funds Management LLC | 13G/A | 7.9% | 3.20M | SEC |
3 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Kiniksa Pharmaceuticals Intl.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Fmr LLC | 6.82M | $328.56M |
| 2 | Rubric Capital Management LP | 3.75M | $180.56M |
| 3 | Baker Bros. Advisors LP | 2.83M | $136.08M |
| 4 | Tang Capital Management LLC | 2.26M | $108.81M |
| 5 | Morgan Stanley | 997.8K | $48.04M |
| 6 | D. E. Shaw & Co., Inc. | 959.3K | $46.19M |
| 7 | Arrowstreet Capital, Limited Partnership | 892.7K | $42.98M |
| 8 | Dimensional Fund Advisors LP | 811.9K | $39.09M |
| 9 | Spruce Street Capital LP | 761.1K | $36.65M |
| 10 | Bank Of America Corp /De/ | 735.9K | $35.44M |